0001104659-19-039283.txt : 20190703 0001104659-19-039283.hdr.sgml : 20190703 20190703160030 ACCESSION NUMBER: 0001104659-19-039283 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190701 FILED AS OF DATE: 20190703 DATE AS OF CHANGE: 20190703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Carroll David Francis CENTRAL INDEX KEY: 0001703623 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36080 FILM NUMBER: 19941877 MAIL ADDRESS: STREET 1: ONE UNIVERSITY SQUARE DRIVE, SUITE 280 CITY: PRINCETON STATE: NJ ZIP: 08540 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IVERIC bio, Inc. CENTRAL INDEX KEY: 0001410939 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208185347 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE PENN PLAZA STREET 2: 35TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10119 BUSINESS PHONE: 212-845-8200 MAIL ADDRESS: STREET 1: ONE PENN PLAZA STREET 2: 35TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10119 FORMER COMPANY: FORMER CONFORMED NAME: Ophthotech Corp. DATE OF NAME CHANGE: 20070828 4 1 a4.xml 4 X0306 4 2019-07-01 0 0001410939 IVERIC bio, Inc. ISEE 0001703623 Carroll David Francis C/O IVERIC BIO, INC. ONE PENN PLAZA, 35TH FLOOR NEW YORK NY 10119 0 1 0 0 SVP, CFO and Treasurer Common Stock 2019-07-01 4 M 0 7500 A 16480 D Common Stock 2019-07-02 4 S 0 2773 1.25 D 13707 D Restricted Stock Units 2019-07-01 4 M 0 7500 0.00 D 2026-06-30 Common Stock 7500 7500 D Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on July 1, 2019. On July 1, 2016, the reporting person was granted an award of 30,000 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. /s/ David F. Carroll 2019-07-03